Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 57.18 USD 0.72% Market Closed
Market Cap: 11B USD

Operating Margin

20.2%
Current
Improving
by 7.9%
vs 3-y average of 12.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
20.2%
=
Operating Income
$625.3m
/
Revenue
$3.1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
20.2%
=
Operating Income
$625.3m
/
Revenue
$3.1B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
11B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.4B USD
Loading...

Market Distribution

Higher than 80% of companies in the United States of America
Percentile
80th
Based on 14 112 companies
80th percentile
20.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Biomarin Pharmaceutical Inc
Glance View

In the bustling hub of biotechnology innovation, BioMarin Pharmaceutical Inc. stands as a notable entity, driven by its mission to transform medical research into meaningful treatments for patients worldwide. Founded in 1997 and headquartered in San Rafael, California, BioMarin has carved a niche in the competitive landscape by specializing in therapies for rare genetic diseases. The company navigates the arduous and often uncertain path of drug development by targeting serious, and typically overlooked, medical conditions. BioMarin's expertise lies in leveraging cutting-edge genetic knowledge and technological advances to develop biopharmaceuticals that address unmet medical needs. This focus not only guides its scientific explorations but also informs its business strategy, where the development of drugs like Vimizim and Palynziq for conditions such as Morquio A syndrome and phenylketonuria, respectively, have made substantial impacts. BioMarin's revenue stream is predominantly fueled by these specialized therapies that cater to niche markets, with patients who often have limited treatment alternatives. Unlike traditional pharmaceuticals, BioMarin's portfolio is characterized by its strategic focus on orphan diseases, allowing it to capitalize on regulatory incentives designed to encourage the development of treatments for rare disorders. This approach provides market exclusivity and premium pricing potential, contributing to its financial robustness. Additionally, BioMarin's continuous investment in research and development ensures a dynamic pipeline aiming to introduce new innovations. This cycle of discovery and commercialization effectively sustains its growth trajectory, allowing BioMarin to not only thrive financially but also deliver on its commitment to improve patient lives with ultra-rare conditions.

BMRN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
20.2%
=
Operating Income
$625.3m
/
Revenue
$3.1B
What is Biomarin Pharmaceutical Inc's current Operating Margin?

The current Operating Margin for Biomarin Pharmaceutical Inc is 20.2%, which is above its 3-year median of 12.3%.

How has Operating Margin changed over time?

Over the last 3 years, Biomarin Pharmaceutical Inc’s Operating Margin has increased from 0% to 20.2%. During this period, it reached a low of 0% on Sep 30, 2022 and a high of 27.1% on Jun 30, 2025.

Back to Top